Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study.
Treatment of seasonal influenza viral infections using antivirals such as neuraminidase inhibitors (NAIs) has been proven effective if administered within 48h post-infection. However, there is growing evidence that antiviral treatment of infections with avian-derived strains even as late as 6 days post-infection (dpi) can significantly reduce infection severity and duration. Using a mathematical model of in-host influenza viral infections which can capture the kinetics of both a short-lived, typical, seasonal infection and a severe infection exhibiting sustained viral titer, we explore differences in the effects of NAI treatment on both types of influenza viral infections. Comparison of our model's behavior against experimental data from patients naturally infected with avian strains yields estimates for the times at which patients were infected that are consistent with those reported by the patients, and estimates of drug efficacies that are lower for patients who died than for those who recovered. In addition, our model suggests that the sustained, high, viral titers often seen in more severe influenza virus infections are the reason why antiviral treatment delayed by as much as 6 dpi will still lead to reduced viral titers and shortened illness. We conclude that NAIs may be an effective and beneficial treatment strategy against more severe strains of influenza virus characterized by high, sustained, viral titers. We believe that our mathematical model will be an effective tool in guiding treatment of severe influenza viral infections with antivirals.
Dobrovolny
Hana M
HM
Department of Physics, Ryerson University, Toronto, Ontario, Canada. hdobrovo@ryerson.ca
Gieschke
Ronald
R
Davies
Brian E
BE
Jumbe
Nelson L
NL
Beauchemin
Catherine A A
CA
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D001717:Birds / Q000821:virology; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D005585:Influenza in Birds / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D007251:Influenza, Human / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D008954:Models, Biological; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053139:Oseltamivir / Q000494:pharmacology / Q000627:therapeutic use; D019562:Viral Load / Q000187:drug effects
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D053139:Oseltamivir; D009439:Neuraminidase